These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

746 related items for PubMed ID: 19948057

  • 1. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.
    BMC Med Genomics; 2009 Nov 30; 2():67. PubMed ID: 19948057
    [Abstract] [Full Text] [Related]

  • 2. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.
    Pancreatology; 2012 Nov 30; 12(2):146-55. PubMed ID: 22487525
    [Abstract] [Full Text] [Related]

  • 3. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, Sun KH, Sun GH, Chang SY, Yu DS, Hsiao PW, Huang SM, Cha TL.
    PLoS One; 2013 Nov 30; 8(9):e73401. PubMed ID: 24023871
    [Abstract] [Full Text] [Related]

  • 4. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
    Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD.
    Invest New Drugs; 2013 Aug 30; 31(4):845-57. PubMed ID: 23299388
    [Abstract] [Full Text] [Related]

  • 5. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F, Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, Wen-Li Z, Pei-Fang X, He Z, Guang-Hao S, Yan-Hong L, Yi-Ping L, Yun-Yun X, Hui-Ting Z, Yi W, Mei-Fang J, Lin L, Jian N, Shao-Yan H, Xue-Ming Z, Xing F, Jian W, Jian P.
    PLoS One; 2015 Aug 30; 10(7):e0126566. PubMed ID: 26176219
    [Abstract] [Full Text] [Related]

  • 6. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A.
    Amino Acids; 2017 Mar 30; 49(3):517-528. PubMed ID: 27761756
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
    Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L.
    Epigenetics; 2013 Sep 30; 8(9):907-20. PubMed ID: 23880963
    [Abstract] [Full Text] [Related]

  • 8. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A.
    Melanoma Res; 2013 Oct 30; 23(5):341-8. PubMed ID: 23963286
    [Abstract] [Full Text] [Related]

  • 9. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.
    Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Fränk M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R.
    Apoptosis; 2012 Dec 30; 17(12):1300-15. PubMed ID: 23011180
    [Abstract] [Full Text] [Related]

  • 10. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S, Mani J, Stastny M, Makarević J, Juengel E, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    Invest New Drugs; 2013 Apr 30; 31(2):265-72. PubMed ID: 22801803
    [Abstract] [Full Text] [Related]

  • 11. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M, Lassmann S.
    Epigenetics; 2015 Apr 30; 10(5):431-45. PubMed ID: 25923331
    [Abstract] [Full Text] [Related]

  • 12. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y, Liu W, Zhang L, Jia G.
    Med Sci Monit; 2017 Oct 29; 23():5150-5157. PubMed ID: 29080899
    [Abstract] [Full Text] [Related]

  • 13. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y.
    J Cancer Res Clin Oncol; 2016 Feb 29; 142(2):379-87. PubMed ID: 26314218
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW, Liao LD, Yang Q, Chen Y, Nie PJ, Zhang XJ, Xie JJ, Shan BE, Zhao LM, Xu LY, Li EM.
    Cell Biochem Funct; 2018 Dec 29; 36(8):398-407. PubMed ID: 30484863
    [Abstract] [Full Text] [Related]

  • 15. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ, Dedes I, Imesch P, von Bueren AO, Fink D, Fedier A.
    Anticancer Drugs; 2009 Jun 29; 20(5):321-33. PubMed ID: 19322073
    [Abstract] [Full Text] [Related]

  • 16. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma.
    Jeon YJ, Ko SM, Cho JH, Chae JI, Shim JH.
    Int J Mol Med; 2013 Oct 29; 32(4):860-6. PubMed ID: 23877235
    [Abstract] [Full Text] [Related]

  • 17. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
    Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW.
    Cell Death Dis; 2013 Feb 28; 4(2):e519. PubMed ID: 23449455
    [Abstract] [Full Text] [Related]

  • 18. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N, Cheng T, Irwin ME, Donnella H, Singh MM, Chandra J.
    Cancer Chemother Pharmacol; 2018 Mar 28; 81(3):483-495. PubMed ID: 29313067
    [Abstract] [Full Text] [Related]

  • 19. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.
    Urol Oncol; 2013 Nov 28; 31(8):1770-9. PubMed ID: 22944197
    [Abstract] [Full Text] [Related]

  • 20. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G.
    Clin Epigenetics; 2018 Jul 31; 10(1):100. PubMed ID: 30064501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.